Company intelligence / Profile preview
ROME Therapeutics
Boston, Massachusetts, United Statesrometx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ROME has nominated a development candidate for autoimmune diseases and presented preclinical data showing their LINE-1 RT inhibitors demonstrated neuroprotective effects in Parkinson's disease models, with a dose-dependent decrease in α-synuclein expression.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Small molecules (LINE-1 reverse transcriptase inhibitors)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on ROME Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ROME Therapeutics.